Volume 20 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
SUN Lu-fan, JIA Da-lin. Clinical characteristics of patients with extremely high level of high-density lipoprotein cholesterol[J]. Chinese Journal of General Practice, 2022, 20(1): 11-13, 79. doi: 10.16766/j.cnki.issn.1674-4152.002264
Citation: SUN Lu-fan, JIA Da-lin. Clinical characteristics of patients with extremely high level of high-density lipoprotein cholesterol[J]. Chinese Journal of General Practice, 2022, 20(1): 11-13, 79. doi: 10.16766/j.cnki.issn.1674-4152.002264

Clinical characteristics of patients with extremely high level of high-density lipoprotein cholesterol

doi: 10.16766/j.cnki.issn.1674-4152.002264
Funds:

 81670320

  • Received Date: 2020-10-27
    Available Online: 2022-03-03
  •   Objective  Extremely high level of high-density lipoprotein cholesterol (HDL-C) has been proven to increase cardiovascular mortality. This study aimed to investigate clinical characteristics of cardiovascular patients with extremely high level of HDL-C, providing information for further research concerning the relationship between HDL-C and cardiovascular diseases, as well as mechanisms of HDL metabolism.  Methods  All adult blood-lipid data in the Department of Cardiology in the First Hospital of China Medical University throughout the entire year of 2019 were retrospectively analysed. Extremely high level of HDL-C was defined as HDL-C ≥ 2.59 mmol/L (100 mg/dL). Gender, age, and medical information of each patient were evaluated. Their lipid profiles were compared with healthy individuals who underwent a checkup in the same hospital during the same period with matched gender and age.  Results  A total of 20 655 patients were included in the final analysis, and patients with an extremely high level of HDL-C covered only 0.16%; they were primarily females and outpatients. Their average age was (60.21±10.27) years, higher than those with normal HDL-C. Their average total cholesterol (TC) level, triglyceride (TG) level, low-density lipoprotein cholesterol (LDL-C) level, and non-high-density lipoprotein cholesterol (non HDL-C) were (6.22±0.95) mmol/L, (0.82±0.36) mmol/L, (3.05±0.75) mmol/L, and (3.30±0.80) mmol/L, respectively. Compared with matched healthy individuals, they had elevated TC and HDL-C/TC ratio (P < 0.001), reduced TG (P < 0.001), and comparable LDL-C (P=0.756) and non HDL-C (P=0.058), irrespective of gender.  Conclusion  Patients with extremely high HDL-C are primarily females and outpatients with elder age. Compared with matched healthy individuals, they have reduced TG and comparable LDL-C and non-HDL-C, probably indicating irrelevance between increased cardiovascular risks and LDL-C, TG, and apolipoprotein B.

     

  • loading
  • [1]
    LORENZATTI A J, TOTH P P. New perspectives on atherogenic dyslipidaemia and cardiovascular disease[J]. Eur Cardiol, 2020, 15(1): 1-9.
    [2]
    温宁馨, 祖凌云. 对于升高高密度脂蛋白药物胆固醇酯转运蛋白抑制剂的研究进展及其机制的探讨[J]. 中国心血管杂志, 2017, 22(3): 231-233. doi: 10.3969/j.issn.1007-5410.2017.03.017
    [3]
    MADSEN C M, VARBO A, NORDESTGAARD B G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: Two prospective cohort studies[J]. Eur Heart J, 2017, 38(32): 2478-2486. doi: 10.1093/eurheartj/ehx163
    [4]
    HIRATA A, SUGIYAMA D, WATANABE M, et al. Association of extremely high levels of high-density lipoprotein cholesterol with cardiovascular mortality in a pooled analysis of 9 cohort studies including 43, 407 individuals: The EPOCH-JAPAN study[J]. J Clin Lipidol, 2018, 12(3): 674-684. doi: 10.1016/j.jacl.2018.01.014
    [5]
    JOMARD A, OSTO E. High density lipoproteins: Metabolism, function, and therapeutic potential[J]. Front Cardiovasc Med, 2020, 7(1): 39.
    [6]
    黄冲, 唐朝克. 影响高密度脂蛋白胆固醇水平的相关基因的研究进展[J]. 中南医学科学杂志, 2017, 45(3): 299-302, 320. https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY201703021.htm
    [7]
    HELGADOTTIR A, SULEM P, THORGEIRSSON G, et al. Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease[J]. Eur Heart J, 2018, 39(23): 2172-2178. doi: 10.1093/eurheartj/ehy169
    [8]
    ZANONI P, KHETARPAL S A, LARACH D B, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease[J]. Science, 2016, 351(6278): 1166-1171. doi: 10.1126/science.aad3517
    [9]
    ERTEK S. High-density lipoprotein (HDL) dysfunction and the future of HDL[J]. Curr Vasc Pharmacol, 2018, 16(5): 490-498. doi: 10.2174/1570161115666171116164612
    [10]
    FENG M, DARABI M, TUBEUF E, et al. Free cholesterol transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis underlies the U-shape relationship between HDL-cholesterol and cardiovascular disease[J]. Eur J Prev Cardiol, 2020, 27(15): 1606-1616. doi: 10.1177/2047487319894114
    [11]
    GRUNDY S M, STONE N J, BAILEY A L, et al. 2018 AHA/ ACC/ AACVPR/ AAPA/ ABC/ ACPM/ ADA/ AGS/ APhA/ ASPC/ NLA/ PCNA Guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2019, 73(24): e285-e350. doi: 10.1016/j.jacc.2018.11.003
    [12]
    MACH F, BAIGENT C, CATAPANO A L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188. doi: 10.1093/eurheartj/ehz455
    [13]
    诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中华心血管病杂志, 2016, 44(10): 833-853. doi: 10.3760/cma.j.issn.0253-3758.2016.10.005
    [14]
    罗兰, 董春江, 李欣宇, 等. 大连地区居民非高密度脂蛋白胆固醇、低密度脂蛋白胆固醇与心血管危险因素聚集的相关性研究[J]. 中华糖尿病杂志, 2020, 12(11): 885-890. doi: 10.3760/cma.j.cn115791-20200506-00267
    [15]
    中华医学会心血管病学分会预防学组. 动脉粥样硬化患者甘油三酯升高的管理中国专家共识[J]. 中华全科医学, 2019, 17(5): 709-713. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY201905002.htm
    [16]
    马依彤. 动脉粥样硬化患者甘油三酯升高的管理中国专家共识要点与解读[J]. 中国循环杂志, 2019, 34(S1): 66-68. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXH2019S1015.htm
    [17]
    张宁, 刘文娴. 高密度脂蛋白胆固醇与冠状动脉粥样硬化性心脏病及冠状动脉多支病变的相关性研究[J]. 中国医药, 2019, 14(7): 969-972. doi: 10.3760/j.issn.1673-4777.2019.07.003
    [18]
    包金兰, 孙润陆, 黄灿霞, 等. 老年高水平高密度脂蛋白胆固醇冠心病患者冠脉病变的回顾性分析[J]. 中山大学学报(医学科学版), 2016, 37(4): 625-629. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201604024.htm
    [19]
    TAKAEKO Y, MATSUI S, KAJIKAWA M, et al. Association of extremely high levels of high-density lipoprotein cholesterol with endothelial dysfunction in men[J]. J Clin Lipidol, 2019, 13(4): 664-672. doi: 10.1016/j.jacl.2019.06.004
    [20]
    MURPHY S A, PEDERSEN T R, GACIONG Z A, et al. Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: A prespecified analysis from the FOURIER trial[J]. JAMA Cardiol, 2019, 4(7): 613-619. doi: 10.1001/jamacardio.2019.0886
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Article Metrics

    Article views (671) PDF downloads(49) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return